{"id":55590,"date":"2024-02-07T05:32:09","date_gmt":"2024-02-07T05:32:09","guid":{"rendered":"https:\/\/medsname.com\/atomoxet\/"},"modified":"2026-04-30T10:24:46","modified_gmt":"2026-04-30T10:24:46","slug":"atomoxet","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/atomoxet\/","title":{"rendered":"\u0391\u03c4\u03bf\u03bc\u03bf\u03be\u03b5\u03c4"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u0391\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Atomoxet (Atomoxetine 10 \/ 18 \/ 25 \/ 40 \/ 60 \/ 80 mg) is a selective noradrenaline reuptake inhibitor for ADHD in children, adolescents, and adults. Non-stimulant \u2014 no abuse potential, no controlled-substance scheduling. Useful when stimulants are unsuitable, ineffective, or contraindicated.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Atomoxet at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> \u2014 \u03c0\u03b1\u03c1\u03ac\u03b8\u03c5\u03c1\u03bf \u03ac\u03c6\u03b9\u03be\u03b7\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03ae \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7 \u2014 \u03ba\u03b1\u03b9 \u03b4\u03b9\u03ba\u03b1\u03b9\u03bf\u03cd\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03c6\u03bf\u03c3\u03af\u03c9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. \u0394\u03b9\u03b1\u03c4\u03af\u03b8\u03b5\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03c1\u03bf\u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2.<\/p>\n

What Atomoxet is and how it works<\/h2>\n

Atomoxet is a 10 \/ 18 \/ 25 \/ 40 \/ 60 \/ 80 mg atomoxetine capsule supplied by Intas. Atomoxetine selectively inhibits the noradrenaline reuptake transporter (NET), increasing synaptic noradrenaline and \u2014 indirectly via cortical NA-DA crosstalk \u2014 frontal-cortex dopamine, without affecting striatal dopamine. The latter is what differentiates atomoxetine from stimulants: no euphoria, no abuse potential, no controlled-substance scheduling.<\/p>\n

\nSlow onset \u2014 not a same-day medication<\/strong><\/p>\n

Stimulants work within 30\u201360 minutes of the first dose. Atomoxetine takes 2\u20134 weeks for initial response and 8\u201312 weeks for full effect. Patients (and parents) expecting stimulant-like immediate change will be disappointed and discontinue. Set the expectation at initiation.<\/p>\n<\/div>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n\n\n\n\n\n\n\n\n
\u0391\u03c3\u03b8\u03b5\u03bd\u03ae\u03c2<\/th>\n\u0395\u03ba\u03ba\u03af\u03bd\u03b7\u03c3\u03b7<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n\u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf<\/th>\n<\/tr>\n<\/thead>\n
Children & adolescents \u2264 70 kg<\/td>\n0.5 mg\/kg\/day \u00d7 3 d<\/td>\n1.2 mg\/kg\/day<\/td>\n1.4 mg\/kg or 100 mg<\/td>\n<\/tr>\n
Children & adolescents > 70 kg<\/td>\n40 mg OD \u00d7 3 d<\/td>\n80 mg OD<\/td>\n100 mg OD<\/td>\n<\/tr>\n
Adults<\/td>\n40 mg OD \u00d7 7 d<\/td>\n80 mg OD<\/td>\n100 mg<\/td>\n<\/tr>\n
Strong CYP2D6 inhibitor \/ poor metaboliser<\/td>\n0.5 mg\/kg or 40 mg<\/td>\n0.5 \u00d7 normal target<\/td>\nby tolerability<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Can be given once daily morning or split BID (morning + late afternoon \u2014 avoid evening because of insomnia).<\/p>\n

\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\nSuicidality black-box (paediatric)<\/strong><\/p>\n

Atomoxetine carries an FDA black-box warning for increased suicidal ideation in children and adolescents, particularly in the first month and at dose changes. Monitor closely for behaviour change in paediatric patients on initiation.<\/p>\n<\/div>\n

\nHepatotoxicity \u2014 rare<\/strong><\/p>\n

Rare cases of severe hepatic injury have been reported. Stop immediately if jaundice, dark urine, RUQ pain, fatigue, or unexplained nausea appear. Do not restart after definite hepatic injury.<\/p>\n<\/div>\n

\n\u039a\u03b1\u03c1\u03b4\u03b9\u03b1\u03b3\u03b3\u03b5\u03b9\u03b1\u03ba\u03ac<\/strong><\/p>\n

Atomoxetine produces small mean increases in BP (+2 mmHg) and HR (+5 bpm). Greater rises occasionally seen in adults. Check BP and HR at baseline, at each dose change, and at follow-up. Avoid in serious cardiac structural abnormality, severe cardiovascular disease, or pheochromocytoma.<\/p>\n<\/div>\n

\nGrowth (paediatric)<\/strong><\/p>\n

Mild reductions in growth velocity reported in children on atomoxetine \u2014 usually catch up over time. Plot height and weight at every visit.<\/p>\n<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n